• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

数字微流控平台用于多重酶联免疫分析:在新生儿溶酶体贮积病筛查中的应用。

Digital microfluidic platform for multiplexing enzyme assays: implications for lysosomal storage disease screening in newborns.

机构信息

Advanced Liquid Logic, Research Triangle Park, NC, USA.

出版信息

Clin Chem. 2011 Oct;57(10):1444-51. doi: 10.1373/clinchem.2011.163139. Epub 2011 Aug 22.

DOI:10.1373/clinchem.2011.163139
PMID:21859904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8917906/
Abstract

BACKGROUND

Newborn screening for lysosomal storage diseases (LSDs) has been gaining considerable interest owing to the availability of enzyme replacement therapies. We present a digital microfluidic platform to perform rapid, multiplexed enzymatic analysis of acid α-glucosidase (GAA) and acid α-galactosidase to screen for Pompe and Fabry disorders. The results were compared with those obtained using standard fluorometric methods.

METHODS

We performed bench-based, fluorometric enzymatic analysis on 60 deidentified newborn dried blood spots (DBSs), plus 10 Pompe-affected and 11 Fabry-affected samples, at Duke Biochemical Genetics Laboratory using a 3-mm punch for each assay and an incubation time of 20 h. We used a digital microfluidic platform to automate fluorometric enzymatic assays at Advanced Liquid Logic Inc. using extract from a single punch for both assays, with an incubation time of 6 h. Assays were also performed with an incubation time of 1 h.

RESULTS

Assay results were generally comparable, although mean enzymatic activity for GAA using microfluidics was approximately 3 times higher than that obtained using bench-based methods, which could be attributed to higher substrate concentration. Clear separation was observed between the normal and affected samples at both 6- and 1-h incubation times using digital microfluidics.

CONCLUSIONS

A digital microfluidic platform compared favorably with a clinical reference laboratory to perform enzymatic analysis in DBSs for Pompe and Fabry disorders. This platform presents a new technology for a newborn screening laboratory to screen LSDs by fully automating all the liquid-handling operations in an inexpensive system, providing rapid results.

摘要

背景

由于酶替代疗法的出现,新生儿溶酶体贮积症(LSD)的筛查引起了相当大的关注。我们提出了一种数字微流控平台,用于快速、多重酶分析酸性α-葡萄糖苷酶(GAA)和酸性α-半乳糖苷酶,以筛查庞贝病和法布里病。结果与使用标准荧光法获得的结果进行了比较。

方法

我们在杜克生化遗传学实验室使用 3 毫米打孔器对 60 份未经识别的新生儿干血斑(DBS)以及 10 份庞贝病和 11 份法布里病样本进行了基于工作台的荧光酶分析,每种测定的孵育时间为 20 小时。我们使用数字微流控平台在 Advanced Liquid Logic Inc. 自动进行荧光酶分析,对于两种测定,使用单个打孔器提取的提取物,孵育时间为 6 小时。还进行了孵育时间为 1 小时的测定。

结果

测定结果通常是可比的,尽管使用微流控的 GAA 酶活性平均值大约是使用基于工作台的方法获得的酶活性平均值的 3 倍,这可能归因于较高的底物浓度。使用数字微流控在 6 小时和 1 小时孵育时间,在正常和受影响的样本之间观察到明显的分离。

结论

与临床参考实验室相比,数字微流控平台在 DBS 中进行庞贝病和法布里病的酶分析表现良好。该平台为新生儿筛查实验室提供了一种新技术,通过在廉价系统中完全自动化所有的液体处理操作,快速提供结果,从而筛选 LSD。

相似文献

1
Digital microfluidic platform for multiplexing enzyme assays: implications for lysosomal storage disease screening in newborns.数字微流控平台用于多重酶联免疫分析:在新生儿溶酶体贮积病筛查中的应用。
Clin Chem. 2011 Oct;57(10):1444-51. doi: 10.1373/clinchem.2011.163139. Epub 2011 Aug 22.
2
Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform.采用数字微流控平台对庞贝氏病、法布雷病、亨特综合征、戈谢病和黏多糖贮积症进行多重新生儿筛查。
Clin Chim Acta. 2013 Sep 23;424:12-8. doi: 10.1016/j.cca.2013.05.001. Epub 2013 May 7.
3
Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry.使用串联质谱法对六种溶酶体贮积症进行新生儿筛查的初步研究。
Mol Genet Metab. 2016 Aug;118(4):304-9. doi: 10.1016/j.ymgme.2016.05.015. Epub 2016 May 20.
4
A tandem mass spectrometry triplex assay for the detection of Fabry, Pompe, and mucopolysaccharidosis-I (Hurler).用于检测 Fabry、Pompe 和黏多糖贮积症-I(Hurler)的串联质谱三联检测法。
Clin Chem. 2010 Dec;56(12):1854-61. doi: 10.1373/clinchem.2010.152009. Epub 2010 Oct 12.
5
Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri.溶酶体贮积症筛查实施情况:密苏里州全面人群试点测试头六个月的发现。
J Pediatr. 2015 Jan;166(1):172-7. doi: 10.1016/j.jpeds.2014.09.023. Epub 2014 Oct 18.
6
Novel application of digital microfluidics for the detection of biotinidase deficiency in newborns.数字微流控技术在新生儿生物素酶缺乏症检测中的新应用。
Clin Biochem. 2013 Dec;46(18):1889-91. doi: 10.1016/j.clinbiochem.2013.09.003. Epub 2013 Sep 11.
7
Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.通过新生儿筛查早期发现庞贝病是可行的:台湾筛查项目的结果
Pediatrics. 2008 Jul;122(1):e39-45. doi: 10.1542/peds.2007-2222. Epub 2008 Jun 2.
8
Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry.采用串联质谱技术从新生儿血斑中鉴定出患有法布雷病、庞贝病或黏多糖贮积症-I 的婴儿。
J Pediatr. 2013 Aug;163(2):498-503. doi: 10.1016/j.jpeds.2013.01.031. Epub 2013 Mar 1.
9
Lysosomal storage disorder 4+1 multiplex assay for newborn screening using tandem mass spectrometry: application to a small-scale population study for five lysosomal storage disorders.基于串联质谱的溶酶体贮积症 4+1 多重分析新生儿筛查:在五例溶酶体贮积症的小规模人群研究中的应用。
Clin Chim Acta. 2012 Aug 16;413(15-16):1270-3. doi: 10.1016/j.cca.2012.04.012. Epub 2012 Apr 21.
10
Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.新生儿溶酶体贮积症的筛查:奥地利全国性研究的可行性和发病率。
Lancet. 2012 Jan 28;379(9813):335-41. doi: 10.1016/S0140-6736(11)61266-X. Epub 2011 Nov 29.

引用本文的文献

1
Open and closed microfluidics for biosensing.用于生物传感的开放式和封闭式微流体技术。
Mater Today Bio. 2024 Apr 4;26:101048. doi: 10.1016/j.mtbio.2024.101048. eCollection 2024 Jun.
2
Evaluation, in a highly specialised enzyme laboratory, of a digital microfluidics platform for rapid assessment of lysosomal enzyme activity in dried blood spots.在一个高度专业化的酶实验室中,对用于快速评估干血斑中溶酶体酶活性的数字微流控平台进行评估。
JIMD Rep. 2024 Feb 19;65(2):124-131. doi: 10.1002/jmd2.12413. eCollection 2024 Mar.
3
How mass spectrometry revolutionized newborn screening.质谱技术如何彻底改变新生儿筛查。
J Mass Spectrom Adv Clin Lab. 2024 Jan 30;32:1-10. doi: 10.1016/j.jmsacl.2024.01.006. eCollection 2024 Apr.
4
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes.基于组学的庞贝病代谢表型特征分析方法
Biology (Basel). 2023 Aug 23;12(9):1159. doi: 10.3390/biology12091159.
5
Newborn Screening for Fabry Disease: Current Status of Knowledge.法布里病的新生儿筛查:知识现状
Int J Neonatal Screen. 2023 Jun 5;9(2):31. doi: 10.3390/ijns9020031.
6
Harmonization of Newborn Screening Results for Pompe Disease and Mucopolysaccharidosis Type I.庞贝病和I型黏多糖贮积症新生儿筛查结果的标准化
Int J Neonatal Screen. 2023 Feb 27;9(1):11. doi: 10.3390/ijns9010011.
7
A Digital Microfluidic RT-qPCR Platform for Multiple Detections of Respiratory Pathogens.一种用于呼吸道病原体多重检测的数字微流控逆转录定量聚合酶链反应平台。
Micromachines (Basel). 2022 Sep 30;13(10):1650. doi: 10.3390/mi13101650.
8
Bone disease in early detected Gaucher Type I disease: A case report.早期诊断的戈谢病I型中的骨病:一例报告。
JIMD Rep. 2022 Jun 26;63(5):414-419. doi: 10.1002/jmd2.12314. eCollection 2022 Sep.
9
Volumeless reagent delivery: a liquid handling method for adding reagents to microscale droplets without increasing volume.无体积试剂输送:一种在不增加体积的情况下向微尺度液滴中添加试剂的液体处理方法。
Lab Chip. 2022 Jan 18;22(2):286-295. doi: 10.1039/d1lc00906k.
10
Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience.意大利东北部法布里病的新生儿筛查:五年经验的结果。
Biomolecules. 2021 Jun 27;11(7):951. doi: 10.3390/biom11070951.

本文引用的文献

1
Newborn bloodspot screening for lysosomal storage disorders.新生儿溶酶体贮积症血斑筛查。
J Pediatr. 2011 Jul;159(1):7-13.e1. doi: 10.1016/j.jpeds.2011.02.026. Epub 2011 Apr 13.
2
Hemoglobin precipitation greatly improves 4-methylumbelliferone-based diagnostic assays for lysosomal storage diseases in dried blood spots.血红蛋白沉淀极大地改善了基于 4-甲基伞形酮的干血斑溶酶体贮积病诊断检测。
Mol Genet Metab. 2011 Jan;102(1):44-8. doi: 10.1016/j.ymgme.2010.09.008. Epub 2010 Sep 26.
3
A tandem mass spectrometry triplex assay for the detection of Fabry, Pompe, and mucopolysaccharidosis-I (Hurler).用于检测 Fabry、Pompe 和黏多糖贮积症-I(Hurler)的串联质谱三联检测法。
Clin Chem. 2010 Dec;56(12):1854-61. doi: 10.1373/clinchem.2010.152009. Epub 2010 Oct 12.
4
Newborn screening for neuropathic lysosomal storage disorders.新生儿神经病变溶酶体贮积症筛查。
J Inherit Metab Dis. 2010 Aug;33(4):381-6. doi: 10.1007/s10545-010-9130-6. Epub 2010 Jun 8.
5
Newborn screening of lysosomal storage disorders.新生儿溶酶体贮积症筛查。
Clin Chem. 2010 Jul;56(7):1071-9. doi: 10.1373/clinchem.2009.141622. Epub 2010 May 20.
6
Digital microfluidics: a future technology in the newborn screening laboratory?数字微流控技术:新生儿筛查实验室的未来技术?
Semin Perinatol. 2010 Apr;34(2):163-9. doi: 10.1053/j.semperi.2009.12.008.
7
Pompe disease in infants: improving the prognosis by newborn screening and early treatment.婴儿庞贝病:通过新生儿筛查和早期治疗改善预后
Pediatrics. 2009 Dec;124(6):e1116-25. doi: 10.1542/peds.2008-3667.
8
Current enzyme replacement therapy for the treatment of lysosomal storage diseases.目前用于治疗溶酶体贮积症的酶替代疗法。
Pediatr Ann. 2009 Aug;38(8):448-55. doi: 10.3928/00904481-20090723-09.
9
Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).台湾地区对法布里病进行的新生儿筛查显示,迟发型GLA突变c.936+919G>A(IVS4+919G>A)的发病率很高。
Hum Mutat. 2009 Oct;30(10):1397-405. doi: 10.1002/humu.21074.
10
Newborn screening for Krabbe disease: the New York State model.克拉贝病的新生儿筛查:纽约州模式。
Pediatr Neurol. 2009 Apr;40(4):245-52; discussion 253-5. doi: 10.1016/j.pediatrneurol.2008.11.010.